Dylan Daniel

5.8k total citations · 2 hit papers
23 papers, 4.5k citations indexed

About

Dylan Daniel is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Dylan Daniel has authored 23 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Dylan Daniel's work include Immunotherapy and Immune Responses (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Dylan Daniel is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Dylan Daniel collaborates with scholars based in United States, Switzerland and France. Dylan Daniel's co-authors include Dale R. Wegmann, Lisa M. Coussens, Yoko Oei, Brian Ruffell, Nancy Pryer, James Sutton, Lisa Sevenich, Daniela F. Quail, Alicia Pedraza and Marsha L. Quick and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Dylan Daniel

23 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

2013 1.8k citations Stephanie M. Pyonteck, Leila Akkari et al. Nature Medicine profile →
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

2014 758 citations Brian Ruffell, Vivien W. Chan et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dylan Daniel United States	15	3.0k	1.6k	1.2k	626	495	23	4.5k
Julian Dyson United Kingdom	30	2.1k 0.7×	732 0.5×	1.1k 0.9×	605 1.0×	1.2k 2.4×	64	4.1k
Thierry Rème France	43	1.8k 0.6×	1.4k 0.9×	2.5k 2.2×	264 0.4×	545 1.1×	102	5.4k
Philip D. King United States	34	1.4k 0.5×	1.1k 0.7×	1.5k 1.3×	310 0.5×	156 0.3×	76	3.5k
Agnieszka E. Gorska United States	31	1.3k 0.4×	3.0k 1.9×	3.2k 2.7×	278 0.4×	232 0.5×	48	5.5k
Iacovos P. Michael Canada	28	578 0.2×	1.1k 0.7×	2.6k 2.2×	483 0.8×	1.0k 2.1×	43	4.6k
Joaquı́n Teixidó Spain	39	1.3k 0.4×	1.6k 1.0×	2.0k 1.8×	240 0.4×	233 0.5×	71	4.4k
Wendy W. Pang United States	13	2.4k 0.8×	1.0k 0.7×	1.4k 1.2×	211 0.3×	380 0.8×	41	4.2k
Yoko Oei United States	12	1.9k 0.6×	1.1k 0.7×	1.4k 1.2×	170 0.3×	541 1.1×	17	3.6k
Laura Strauss United States	29	3.2k 1.0×	2.0k 1.2×	1.1k 1.0×	124 0.2×	202 0.4×	46	4.5k
Neta Erez Israel	35	1.9k 0.6×	3.1k 1.9×	2.6k 2.2×	183 0.3×	303 0.6×	61	5.7k

Countries citing papers authored by Dylan Daniel

Since Specialization

Citations

This map shows the geographic impact of Dylan Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dylan Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dylan Daniel more than expected).

Fields of papers citing papers by Dylan Daniel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dylan Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dylan Daniel. The network helps show where Dylan Daniel may publish in the future.

Co-authorship network of co-authors of Dylan Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of Dylan Daniel. A scholar is included among the top collaborators of Dylan Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dylan Daniel. Dylan Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravichandran, Kanchana, Kung Wong Lau, J. Millet, et al.. (2025). Abstract 3127: An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies. Cancer Research. 85(8_Supplement_1). 3127–3127. 1 indexed citations

Berezhnoy, Alexey, Hsin Wang, Na Cai, et al.. (2022). 1078 Conditionally activatable interferon-alpha 2b improves tolerability and exhibits preferential activity in tumors. Regular and Young Investigator Award Abstracts. A1120–A1120. 1 indexed citations

Berezhnoy, Alexey, Hsin Wang, Michael B. Winter, et al.. (2022). Abstract 2071: Probody-interferon-alpha 2b combines antitumor activity with improved tolerability. Cancer Research. 82(12_Supplement). 2071–2071. 1 indexed citations

Berezhnoy, Alexey, Hsin Wang, Hikmat Assi, et al.. (2021). 706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b. SHILAP Revista de lepidopterología. A735–A735. 6 indexed citations

Scolan, Erwan Le, Tiffany Tse, Michael Krimm, et al.. (2019). Abstract 3202: A probody drug conjugate targeting CD166 (ALCAM) enhances preclinical antitumor activity of a probody therapeutic targeting PD-1. Cancer Research. 79(13_Supplement). 3202–3202. 2 indexed citations

Daniel, Dylan, et al.. (2018). Abstract 5691: Evaluation of immunomodulatory agents in classically immunologically 'cold' cancers using syngeneic mouse models of breast and ovarian cancer. Cancer Research. 78(13_Supplement). 5691–5691. 3 indexed citations

Sun, Jianping, Michael A. Sheard, Hongwei Wu, et al.. (2018). Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. International Journal of Cancer. 143(6). 1483–1493. 35 indexed citations

Grünewald, Jan, Heath E. Klock, Susan E. Cellitti, et al.. (2015). Efficient Preparation of Site-Specific Antibody–Drug Conjugates Using Phosphopantetheinyl Transferases. Bioconjugate Chemistry. 26(12). 2554–2562. 35 indexed citations

Ruffell, Brian, Vivien W. Chan, Christine M. Ho, et al.. (2014). Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell. 26(5). 623–637. 758 indexed citations breakdown →

10.

Strachan, Debbie, Brian Ruffell, Yoko Oei, et al.. (2013). CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8⁺T cells. OncoImmunology. 2(12). e26968–e26968. 314 indexed citations

11.

Pyonteck, Stephanie M., Leila Akkari, Alberto J. Schuhmacher, et al.. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature Medicine. 19(10). 1264–1272. 1799 indexed citations breakdown →

12.

Wilson, Nicholas S., Becky Yang, Annie Yang, et al.. (2011). An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells. Cancer Cell. 19(1). 101–113. 213 indexed citations

13.

Daniel, Dylan & Nick Wilson. (2008). Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?. Current Cancer Drug Targets. 8(2). 124–131. 45 indexed citations

14.

Daniel, Dylan, Becky Yang, Klára Tótpál, et al.. (2007). Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin’s lymphoma. Molecular Cancer Therapeutics. 6. 3 indexed citations

15.

Maecker, Heather, Eugene Varfolomeev, Frank Kischkel, et al.. (2005). TWEAK Attenuates the Transition from Innate to Adaptive Immunity. Cell. 123(5). 931–944. 202 indexed citations

16.

Daniel, Dylan, Nicole Meyer-Morse, Emily K. Bergsland, et al.. (2003). Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells. The Journal of Experimental Medicine. 197(8). 1017–1028. 140 indexed citations

17.

Cao, Zhu, Dylan Daniel, & Douglas Hanahan. (2002). Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer. 2(1). 11–11. 71 indexed citations

18.

Daniel, Dylan & Dale R. Wegmann. (1996). Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).. Proceedings of the National Academy of Sciences. 93(2). 956–960. 340 indexed citations

19.

Daniel, Dylan, Ronald G. Gill, Nanette C. Schloot, & Dale R. Wegmann. (1995). Epitope specificity, cytokine production profile and diabetogenic activity of insulin‐specific T cell clones isolated from NOD mice. European Journal of Immunology. 25(4). 1056–1062. 302 indexed citations

20.

Gill, Ronald G., Leslie A. Wolf, Dylan Daniel, & Marilyne Coulombe. (1994). CD4+ T cells are both necessary and sufficient for islet xenograft rejection.. PubMed. 26(3). 1203–1203. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact